View in EDS

The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.

Saved in:
Bibliographic Details
Title: The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
Authors: Whitaker JA; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA., Rebolledo PA; Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Abate G; Center for Vaccine Development, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine, Saint Louis University, Saint Louis, MO, USA., Babu TM; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA., Rouphael NG; Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA., Wald A; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., El Sahly HM; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA., Jooss K; Gritstone bio, Inc. Emeryville, CA, USA., Hart MG; Gritstone bio, Inc. Emeryville, CA, USA., Makowski M; The Emmes Company, LLC, Rockville, MD, USA., Mu J; The Emmes Company, LLC, Rockville, MD, USA., Carmack A; The Emmes Company, LLC, Rockville, MD, USA., Archer JI; FHI 360, Durham, NC, USA., Roberts PC; Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA., Makhene M; Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA., Posavad CM; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., McElrath MJ; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., De Rosa SC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Coler R; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA., Montefiori D; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Eaton A; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Suthar MS; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA., Atmar RL; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA., Hoft DF; Center for Vaccine Development, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine, Saint Louis University, Saint Louis, MO, USA; Department of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, MO, USA. Electronic address: daniel.hoft@slu.edu.
Corporate Authors: DMID 20-0034 Study Team
Source: Vaccine [Vaccine] 2026 Apr 02; Vol. 77, pp. 128358. Date of Electronic Publication: 2026 Feb 25.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41740461
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Whitaker+JA%22">Whitaker JA</searchLink>; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Rebolledo+PA%22">Rebolledo PA</searchLink>; Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Abate+G%22">Abate G</searchLink>; Center for Vaccine Development, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine, Saint Louis University, Saint Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Babu+TM%22">Babu TM</searchLink>; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Rouphael+NG%22">Rouphael NG</searchLink>; Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Wald+A%22">Wald A</searchLink>; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22El+Sahly+HM%22">El Sahly HM</searchLink>; Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Jooss+K%22">Jooss K</searchLink>; Gritstone bio, Inc. Emeryville, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hart+MG%22">Hart MG</searchLink>; Gritstone bio, Inc. Emeryville, CA, USA.<br /><searchLink fieldCode="AU" term="%22Makowski+M%22">Makowski M</searchLink>; The Emmes Company, LLC, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Mu+J%22">Mu J</searchLink>; The Emmes Company, LLC, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Carmack+A%22">Carmack A</searchLink>; The Emmes Company, LLC, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Archer+JI%22">Archer JI</searchLink>; FHI 360, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Roberts+PC%22">Roberts PC</searchLink>; Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Makhene+M%22">Makhene M</searchLink>; Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Posavad+CM%22">Posavad CM</searchLink>; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22McElrath+MJ%22">McElrath MJ</searchLink>; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22De+Rosa+SC%22">De Rosa SC</searchLink>; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Coler+R%22">Coler R</searchLink>; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Montefiori+D%22">Montefiori D</searchLink>; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Eaton+A%22">Eaton A</searchLink>; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Suthar+MS%22">Suthar MS</searchLink>; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA.<br /><searchLink fieldCode="AU" term="%22Atmar+RL%22">Atmar RL</searchLink>; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hoft+DF%22">Hoft DF</searchLink>; Center for Vaccine Development, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine, Saint Louis University, Saint Louis, MO, USA; Department of Molecular Microbiology & Immunology, Saint Louis University, Saint Louis, MO, USA. Electronic address: daniel.hoft@slu.edu.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22DMID+20-0034+Study+Team%22">DMID 20-0034 Study Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2026 Apr 02; Vol. 77, pp. 128358. <i>Date of Electronic Publication: </i>2026 Feb 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41740461
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2026.128358
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 128358
    Titles:
      – TitleFull: The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Whitaker JA
      – PersonEntity:
          Name:
            NameFull: Rebolledo PA
      – PersonEntity:
          Name:
            NameFull: Abate G
      – PersonEntity:
          Name:
            NameFull: Babu TM
      – PersonEntity:
          Name:
            NameFull: Rouphael NG
      – PersonEntity:
          Name:
            NameFull: Wald A
      – PersonEntity:
          Name:
            NameFull: El Sahly HM
      – PersonEntity:
          Name:
            NameFull: Jooss K
      – PersonEntity:
          Name:
            NameFull: Hart MG
      – PersonEntity:
          Name:
            NameFull: Makowski M
      – PersonEntity:
          Name:
            NameFull: Mu J
      – PersonEntity:
          Name:
            NameFull: Carmack A
      – PersonEntity:
          Name:
            NameFull: Archer JI
      – PersonEntity:
          Name:
            NameFull: Roberts PC
      – PersonEntity:
          Name:
            NameFull: Makhene M
      – PersonEntity:
          Name:
            NameFull: Posavad CM
      – PersonEntity:
          Name:
            NameFull: McElrath MJ
      – PersonEntity:
          Name:
            NameFull: De Rosa SC
      – PersonEntity:
          Name:
            NameFull: Coler R
      – PersonEntity:
          Name:
            NameFull: Montefiori D
      – PersonEntity:
          Name:
            NameFull: Eaton A
      – PersonEntity:
          Name:
            NameFull: Suthar MS
      – PersonEntity:
          Name:
            NameFull: Atmar RL
      – PersonEntity:
          Name:
            NameFull: Hoft DF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 04
              Text: 2026 Apr 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 77
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1